• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.09
  • VXN 15.15
  • VXO 12.04
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
PTIE (Pain Therapeutics Inc.)
Last Trade 1.24 Dividend/Share 0 PE Ratio -1.48
Date March 27-2019 Dividend Yield 0.000 Return on Assets -60.54
Change 0.08 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.84 Price/Sale null
Ask null LatestEPS Date 2018-12-31 Price to Book 1
Volume null EPS ttm -0.840 Institutional % 19.1
Avg Volume 0.22M Shares Outstanding 17.22M Insider % 78.1
Open 1.19 Float 11.83M Short Ratio null
Prev Close 1.16 Return On Equity -67.6 5 Year Change % -0.968
High 1.27 Consensus EPS 0 2 Year Change % -0.788
Low 1.18 No. of Estimate 0.000 1 Year Change % -0.818
52 Week High 10.8685 EPS Surprise $ null YTD Change % 0.344
52 Week Low 0.76 EPS Surprise Percent 0 6 Month Change % 0.253
52 Week Change -80.982 EBITDA 0M 3 Month Change % 0.550
50 Day MA 1.166 Revenue 0M 1 Month Change % 0.016
200 Day MA Gross Profit 0M 5 Day Change % 0.016
Market Cap 21.35M Cash 0M 30 Day Change % 0.204
Beta 1.926794 Debt 0M Stock Exchange NASDAQ Capital Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in San Mateo, California.